Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Concord Drugs Ltd Performance

Today's Low
35.25
arrowIcon
Today's High
38.00
52 Wk Low
25.56
arrowIcon
52 Wk High
61.50


Open

38

Traded Value (Cr)

72.05 K

Prev. Close

35.46

VWAP

35.7

Volume

2,012

Face Value

10

Concord Drugs Ltd Fundamentals

Market Cap
₹ 35 Cr
P/E Ratio (TTM)
36.56
P/B Ratio
1.00
Debt to Equity
0.52
ROE
5.04 %
EPS (TTM)
0.97
Dividend Yield
0.00%
Book Value
35.40

Click here to know more about Fundamentals

Concord Drugs Ltd Financials

Concord Drugs Ltd Financials

Concord Drugs Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Oct 2023 Sep 2023
Promoters 55.41 % 55.41 % 55.41 % 52.13 %
Retail 44.28 % 44.27 % 44.29 % 47.54 %
Others 0.31 % 0.32 % 0.30 % 0.33 %
FII 0.00 % 0.00 % 0.00 % 0.00 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

55.41%

Retail

44.28%

Others

0.31%

FII

0.00%

Mutual Funds

0.00%

Promoters

55.41%

Retail

44.27%

Others

0.32%

FII

0.00%

Mutual Funds

0.00%

Promoters

55.41%

Retail

44.29%

Others

0.30%

FII

0.00%

Mutual Funds

0.00%

Promoters

52.13%

Retail

47.54%

Others

0.33%

FII

0.00%

Mutual Funds

0.00%

Resistance and Support

₹36.12

PIVOT

resistance-arrow
Resistance
First Resistance₹37.127
Second Resistance₹38.793
Third Resistance₹39.797
support-arrow
Support
First Resistance₹34.457
Second Resistance₹33.453
Third Resistance₹31.787
RSI42.745
MACD-0.349
ADX26.796
CCI-95.054

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day6,3381,88593.69
Week6,1245,37688.61
1 Month6,3775,30881.81
6 Months000.00

About Concord Drugs Ltd

CONCORD DRUGS LIMITED is a public limited company established in 1995, is among the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small volume parenterals, Dry powder ) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide our customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing. The company operates a state of the art, cGMP contract manufacturing Formulation-Fill-Finish facility, providing comprehensive pharmaceutical development and manufacturing services for drug products. The company has two manufacturing facilities built to comply with standards stipulated by Regulatory bodies.

Managing Director

S Nagi Reddy

Founded

1995

NSE Symbol

Concord Drugs Ltd Management

NameDesignation
S Nagi ReddyChairman & Managing Director
K Ramchandra ReddyIndependent Director
Koni ReddyWhole Time Director & CFO
S. Nagavenkata HareeshIndependent Director
S. Manoj Kumar ReddyWhole-time Director
Summela KasuIndependent Director
Namratha NaglaCompany Sec. & Compli. Officer

Concord Drugs Ltd News

Concord Drugs reports consolidated net loss of Rs 0.24 crore in the December 2023 quarter
Sales decline 5.54% to Rs 12.78 crore
Concord Drugs to announce Quarterly Result
On 13 February 2024
Concord Drugs consolidated net profit rises 211.11% in the September 2023 quarter
Sales decline 45.19% to Rs 7.52 crore
Concord Drugs standalone net profit rises 194.44% in the September 2023 quarter
Sales decline 46.21% to Rs 7.38 crore
Concord Drugs to conduct board meeting
On 14 November 2023
Concord Drugs to conduct AGM
On 30 September 2023
Concord Drugs consolidated net profit rises 157.89% in the June 2023 quarter
Sales decline 28.33% to Rs 8.98 crore
Concord Drugs to hold board meeting
On 14 August 2023
Concord Drugs consolidated net profit rises 433.33% in the March 2023 quarter
Sales decline 20.38% to Rs 12.31 crore
Concord Drugs standalone net profit rises 133.33% in the March 2023 quarter
Sales decline 25.36% to Rs 11.54 crore

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,58,304 Cr
₹ 1,493.35
(-1.85 %)
86.97
CIPLA₹ 1,09,708 Cr
₹ 1,358.80
(-1.88 %)
33.36
DIVISLAB₹ 1,00,599 Cr
₹ 3,789.50
(-3.55 %)
73.75
DRREDDY₹ 98,073 Cr
₹ 5,879.05
(-2.93 %)
22.59
ZYDUSLIFE₹ 97,383 Cr
₹ 967.80
(-3.77 %)
36.23

Concord Drugs Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Concord Drugs Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Concord Drugs Ltd's share price is ₹35.81 as of May 9, 2024

Concord Drugs Ltd's P/E ratio is 36.56 times as of May 9, 2024.

Concord Drugs Ltd's most recent financial reports indicate a price-to-book ratio of 1.00, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Concord Drugs Ltd's market is 35 Cr as on May 9, 2024.

The current financial records of Concord Drugs Ltd show a 5.04% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Concord Drugs Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Concord Drugs Ltd's 52-week high and low as of May 9, 2024 are ₹38 and ₹35.25 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Concord Drugs Ltd stands at 55.41%. During the same period, Institutional Investors have shown a slight values are equal in their holdings, values are equal from 0.00% to 0.00%.